Skip to main content

eToro Market Movers Healthcare Stocks: $ANTM $BHC $BMY

The Market Signal was created as a platform to help investors, if you own (NYSE:ANTM), (NYSE:BHC) or (NYSE:BMY) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)

Anthem Enters Strategic Collaboration With Quest Diagnostics To Enhance Care Delivery

https://themarketsignal.com/Free-Report/ANTM

(Click link above or copy, paste and hit enter in your browser for your report)
Anthem Inc. (NYSE:ANTM) has a 100% buying sentiment on eToro. The company has a market capitalization of $69.47 billion. The company has entered a multi-regional strategic initiative agreement with Quest Diagnostics aimed at enhancing care delivery, reducing costs as well as improving the experience of healthcare providers and consumers. The strategic collaboration will focus on consumers ion Georgia, California, Connecticut, Kentucky, Indiana, Missouri, Maine Ohio, New York, Virginia, Wisconsin, and New Hampshire.

The company has appointed Jeffrey Alter as the executive VP IngenioRx and Anthem Health Solutions from September 8, 2020. Alter will serve as a member of Anthem's Senior Leadership Team and will be reporting to the company's CEO and President Gall K Boudreaux.

Bausch Health Reaches Settlement With SEC Regarding Improper Revenue Recognition

https://themarketsignal.com/Free-Report/BHC

(Click link above or copy, paste and hit enter in your browser for your report)

Bausch Health Companies Inc. (NYSE:BHC) is also another stock with 100% buying sentiment on eToro and its market cap is $5.78 billion. The company reached a settlement with the US SEC early this year. The company formerly known as Valeant pharmaceuticals had been accused of engaging in improper revenue recognition and misleading disclosures in earnings presentations and SEC filings. Besides the company agreeing to settle three of its former executives also paid penalties to settle allegations against them.

The company announced that it plans to reduce debt by almost $100 million by redeeming outstanding senior notes and through cash from operations. Bausch Health plans to redeem $100 million in total principal amount of the 5.875% outstanding Senior Notes due 2023.

Bristol-Myers Squibb To Acquire Forbius In Its Efforts For Opdivo-enhancing Treatment

https://themarketsignal.com/Free-Report/BMY

(Click link above or copy, paste and hit enter in your browser for your report)

Bristol-Myers Squibb Co, Inc. (NYSE:BMY) has a market cap of $135.12 billion and it currently has a 100% buying sentiment on eToro. The company has reached an agreement for the acquisition of Forbius for its Portfolio of TGF-beta inhibitors. With the takeover, Bristol Myers Squibb will get control of the clinical-phase inhibitor of TGF-beta 1 and 3 which Forbius is currently developing to increase the activity of immune checkpoint inhibitors.

The company has penned a $475 million deal in upfront and near-term payments to license the interleukin-12 immunotherapy program of Dragonfly Therapeutics. The IL-12 program is an experimental med DF6002 immunoglobulin FC fusion protein that creates an inflammatory tumor microenvironment to enhance anti-tumor responses.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_370850048/2700/2020-09-07T07:00:11

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.